Access Pharmaceuticals, Inc., a biopharmaceutical company focused on cancer and supportive care, announced this morning that it is sponsoring an Oral Mucositis Symposium today for researchers and health care professionals attending the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. later this week. To further educate and build awareness of the debilitating side effect of anticancer treatments, the Oral Mucositis (OM) Symposium will feature leading industry experts covering various topics concerning the disease, from pathogenesis and clinical factors to prevention and management of oral mucositis.
Hosting the OM Symposium is part of Access Pharma’s strategy for its North American commercial launch of MuGard – its FDA-approved product for the management of oral mucositis. On Thursday of this week Access Pharma will present a poster co-authored with its European partner, SpePharm, on the management of oral mucositis at the MASCC Conference and provide updated clinical experience data on MuGard. Access Pharma has already completed its commercial scale production run of MuGard in North America, and commenced the MuGard Centers-of-Excellence Sampling program with leading oncology networks.
“We are delighted to have the opportunity to host an oral mucositis symposium and to present MuGard information and clinical experience to such a broad and prestigious audience at this year’s MASCC conference,” stated Jeffrey Davis, CEO of Access Pharmaceuticals. “Hosting an Oral Mucositis Symposium not only provides the opportunity to obtain valuable perspective from the opinion leaders in the area of oral mucositis, but also enables researchers to learn about the critical importance in preventing and managing this common debilitating side effect.”
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Disclosure: no positions